ICL Group (NYSE: ICL) CEO details major stock option and vesting profile
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
ICL Group Ltd. President & CEO Elad Aharonson reported existing holdings of stock options to buy ICL ordinary shares. These options cover 306,748 underlying shares at an exercise price of $6.39 per share expiring on June 30, 2026, 737,705 underlying shares at $9.39 expiring on February 8, 2027, 1,118,290 underlying shares at $5.87 expiring on April 4, 2029, and 2,308,963 underlying shares at $6.78 expiring on March 13, 2030. Footnotes state that some options are fully vested and exercisable, while others vest in three annual installments from April 4, 2024 and March 13, 2025, including specified vesting percentages.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Aharonson Elad
Role
President & CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Stock Options (Right to Buy) — 306,748 shares (Direct)
Footnotes (1)
- The stock options are fully vested and exercisable. The stock options vest in three equal annual installments from the April 4, 2024, grant date. The stock options vest in three annual installments (37.58%, 37.58%, 24.82%) from the March 13, 2025, grant date. Represents an exercise price of NIS 20.13, converted to U.S. dollars using the Bank of Israel representative exchange rate of $1.00 to NIS 3.149 as of March 27, 2026. The options are held by a Trustee in the name of the Reporting Person. Represents an exercise price of NIS 29.57, converted to U.S. dollars using the Bank of Israel representative exchange rate of $1.00 to NIS 3.149 as of March 27, 2026. Represents an exercise price of NIS 18.47, converted to U.S. dollars using the Bank of Israel representative exchange rate of $1.00 to NIS 3.149 as of March 27, 2026. Represents an exercise price of NIS 21.34, converted to U.S. dollars using the Bank of Israel representative exchange rate of $1.00 to NIS 3.149 as of March 27, 2026.
Key Figures
Option grant 1 exercise price: $6.39 per share
Option grant 2 exercise price: $9.39 per share
Option grant 3 exercise price: $5.87 per share
+3 more
6 metrics
Option grant 1 exercise price
$6.39 per share
Stock options over 306,748 underlying ordinary shares expiring June 30, 2026
Option grant 2 exercise price
$9.39 per share
Stock options over 737,705 underlying ordinary shares expiring February 8, 2027
Option grant 3 exercise price
$5.87 per share
Stock options over 1,118,290 underlying ordinary shares expiring April 4, 2029
Option grant 4 exercise price
$6.78 per share
Stock options over 2,308,963 underlying ordinary shares expiring March 13, 2030
Vesting from April 4, 2024
Three equal annual installments
Footnote states options vest in three equal annual installments from April 4, 2024 grant date
Vesting from March 13, 2025
37.58%, 37.58%, 24.82%
Footnote states options vest in three annual installments from March 13, 2025 grant date
Key Terms
Stock Options (Right to Buy), Ordinary Shares, exercise price, vest in three equal annual installments, +1 more
5 terms
Stock Options (Right to Buy) financial
"security_title: Stock Options (Right to Buy)"
exercise price financial
"Represents an exercise price of NIS 20.13, converted to U.S. dollars"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest in three equal annual installments financial
"The stock options vest in three equal annual installments from the April 4, 2024, grant date."
Trustee financial
"The options are held by a Trustee in the name of the Reporting Person."
A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.
FAQ
What does the ICL (ICL) Form 3 filing by CEO Elad Aharonson show?
The Form 3 shows CEO Elad Aharonson’s existing stock option holdings in ICL Group Ltd.. It details four option grants over ICL ordinary shares, including underlying share amounts, exercise prices in U.S. dollars, expiration dates, and vesting schedules described in the footnotes.
What are the exercise prices of Elad Aharonson’s ICL stock options?
The filing lists exercise prices of $6.39, $9.39, $5.87, and $6.78 per share for different option grants. Footnotes explain these represent converted prices from NIS using a Bank of Israel exchange rate of $1.00 to NIS 3.149 as of March 27, 2026.
How do Elad Aharonson’s ICL stock options vest over time?
Some options are already fully vested and exercisable, according to the footnotes. Other grants vest in three equal annual installments from April 4, 2024, or in three installments of 37.58%, 37.58% and 24.82% from March 13, 2025, creating a staggered vesting profile.
When do Elad Aharonson’s ICL stock options expire?
The options expire on several dates: June 30, 2026, February 8, 2027, April 4, 2029, and March 13, 2030. Each expiration date applies to a specific grant with its own exercise price and number of underlying ICL ordinary shares.
Are Elad Aharonson’s ICL stock options held directly or through a trustee?
The filing shows the options as direct holdings, and a footnote states that some options are held by a Trustee in the name of the Reporting Person. This indicates beneficial ownership remains with Elad Aharonson despite trustee custody.